GlassScriptPhysician profile
Lenora Hirschler
NPI 1801871694
$4,938.57
in general payments reported to CMS, 2019-2025
41 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $320 · 2021: $709 · 2022: $413 · 2023: $656 · 2024: $1,174 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.91 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.50 | 2021-2025 | |
| Novo Nordisk INC | $325.48 | 2019-2025 | Ozempic, Rybelsus |
| Indivior INC. | $313.99 | 2019-2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $269.72 | 2020-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $250.25 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $220.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Lundbeck LLC | $205.96 | 2023-2025 | Rexulti, Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.62 | 2021-2025 | Jardiance |
| Pfizer INC. | $196.67 | 2019-2024 | |
| Glaxosmithkline, LLC. | $172.29 | 2019-2024 | Trelegy Ellipta, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $148.94 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $148.60 | 2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $139.39 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $131.42 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.97 | 2022-2025 | Caplyta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.74 | 2020-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $83.95 | 2019-2025 | Trintellix, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.47 | 2023-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $71.66 | 2019-2021 | |
| Insulet Corporation | $70.28 | 2021-2025 | Omnipod |
| Exact Sciences Corporation | $67.81 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $64.14 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $62.66 | 2019-2024 | Freestyle Libre 3 |
| Allergan, INC. | $62.42 | 2019-2020 | |
| Mylan Specialty L.P. | $61.19 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $54.95 | 2021-2022 | |
| Axsome Therapeutics, INC. | $51.78 | 2025 | Auvelity |
| Biogen, INC. | $47.89 | 2021 | |
| Viatris Specialty LLC | $43.49 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $39.95 | 2024 | Voquezna |
| Medtronic, INC. | $29.74 | 2023 | Intellis Adaptivestim |
| Eisai INC. | $29.69 | 2020 | |
| Verona Pharma, INC. | $25.46 | 2025 | Ohtuvayre |
| Sanofi Pasteur INC. | $25.41 | 2019-2023 | |
| Grifols USA, LLC | $22.30 | 2020 | |
| Ibsa Pharma INC. | $22.16 | 2025 | Licart, Flector, Tirosint |
| Alkermes, INC. | $19.85 | 2024 | Vivitrol |
| Supernus Pharmaceuticals, INC. | $18.50 | 2025 | Qelbree |
| Acadia Pharmaceuticals INC | $17.89 | 2021 | |
| Gilead Sciences, INC. | $17.28 | 2025 | |
| Boston Scientific Corporation | $15.95 | 2025 | Bodyguardian |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lenora Hirschler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.